恩曲他滨
替诺福韦-阿拉芬酰胺
杜鲁特格拉维尔
医学
埃法维伦兹
拉米夫定
药理学
病毒学
人类免疫缺陷病毒(HIV)
病毒载量
乙型肝炎病毒
病毒
抗逆转录病毒疗法
作者
Bronwyn Bosch,Godspower Akpomiemie,Nomathemba Chandiwana,Simiso Sokhela,Andrew Hill,Kaitlyn McCann,Ambar Qavi,Manya Mirchandani,François Venter
摘要
Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin.
科研通智能强力驱动
Strongly Powered by AbleSci AI